
founder scientist — cancer / ai | ex @ICR_London | PhD @BristolRobotLab
London, England
Joined April 2022
- Tweets3.9K
- Following229
- Followers271
- Likes2K
Khalid Abduljabbar retweeted
I am coming home to the UK in December! We will be hosting some @CompoundVC events the first week of December and encourage y'all to join!
-> 12/1 Compound Idea Factory in London - luma.com/o0pq0nw8
-> 12/2 Oxford Biotech Builders Lunch - luma.com/lkvcz7ux
-> 12/3 Cambridge BioxAI Breakfast - luma.com/whjmrsyq
great timing to be finally thinking about a seed-stage biotech PR...
Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...
49
-J&J, which sells Acuvue, paid $4.3Bn for a LASIK business
-by this logic, Lilly should actually be even more incentivized to cure indications it doesn’t collect let's say Novo’s or Pfizer’s refills (ie, where a rival holds the franchise); pure upside lol
why don't they!?
The CEO of Eli Lilly says cures are "not likely."
Bold prediction from the guy selling refills.
An industry that earns more treating you for 30 years than curing you once is never going to be the one yelling "faster."
That's our job.
35
Khalid Abduljabbar retweeted
So excited to share more about what I have been up to. @ProximalVC is a first check fund that loves to partner with founders before incorporation to support ideation and initial GTM strategy.
If you’re building the systems that make discovery smarter, trials faster, manufacturing more resilient, supply chains more transparent or commercial execution more precise - please reach out!
Former SignalFire investor Sahir Raoof raises $27.5M for new fund targeting AI in pharma
spr.ly/6014ByDyxC
would be very nice indeed!
Wouldn’t it be nice to have a biomarker that could help identify patients most likely to benefit from T-DXd?
Earlier this year, we published a pilot study in npj Precision Oncology exploring quantitative HER2 testing to predict T-DXd, with promising results: nature.com/articles/s41698-0…
Excited to present the validation of the High-Sensitivity (HS)-HER2 findings at #SABCS26, during Rapid Fire Oral Session 3!
One step closer to understanding which patients are most likely to benefit from T-DXd.
sabcs.org/events/2026/rapid-…
34
to add, *complete response was achieved in 71.7%* in this study !!
Immunotherapy for Gestational Trophoblastic Neoplasia (GTN)
excellent work led by @EGhorani now out in @NEJMEvidence: "pembrolizumab was associated with durable responses in multidrug-resistant GTN and showed potential activity as adjuvant therapy for poor-prognosis PSTT/ETT"
19
Immunotherapy for Gestational Trophoblastic Neoplasia (GTN)
excellent work led by @EGhorani now out in @NEJMEvidence: "pembrolizumab was associated with durable responses in multidrug-resistant GTN and showed potential activity as adjuvant therapy for poor-prognosis PSTT/ETT"
full paper: evidence.nejm.org/doi/full/1…
editorial:
evidence.nejm.org/doi/full/1…
22
another biotech humbling moments that getting HR 0.58 still wiped ~25% of market value $MRNA
left: pembro, stage III melanoma
right: + mRNA personalized vaccine
1
85
A powerful gene-editing technique has been used to edit DNA directly in a person’s body — the first known instance of such a treatment.
go.nature.com/4Bgi3Yx
1
158
nobody is explaining HOW the breach occurred!?
#ESMO26: The embargo on LBA1, “INTerpath-001: Phase 3 study of the mRNA-based individualised neoantigen therapy intismeran autogene plus pembrolizumab versus pembrolizumab alone for adjuvant treatment of resected stage IIB-IV melanoma”, has been breached. As the data are now publicly available, ESMO has released the information contained in the abstract and has lifted the embargo on the full dataset.
36
there’s some common sense here
the most charitable view would be that hypers *omit* this reality
The AI hype in biotech is just silly now. So your agent took only 12 hours to design a new drug? Great! Now, you still have to spend 5 years running trials and proving it works in humans without killing anyone. If AI does drug design like it does my stock reseach, there are going to be a lot of dead test subjects.
1
38
Khalid Abduljabbar retweeted
One more week to complete our survey! We want to understand what clinicians need to bring ctDNA MRD testing into routine clinical practice. If you care for patients with breast cancer, please take a few minutes to participate and help shape future research!
@nlinmd @stolaney1
Dr. Ilana Schlam (@IlanaSchlam) discussing her new #ctDNA study at the HCC #BreastCancerResearchRetreat. The study is on the use of ctDNA NGS and MRD Assays in Clinical Practice. If you are a licensed clinician who treats patients with #BreastCancer, help us better understand current practice patterns and perceptions regarding the use of circulating tumor DNA (ctDNA) standard next-generation sequencing (#NGS) assays and minimal residual disease (#MRD) assays in breast cancer, across both early-stage and metastatic settings.
👉Study Link: redcap.link/ctdna_provider

























